Form 4: Director Deming Granted 23,800 PHIO Restricted Stock Units

Phio Pharmaceuticals Corp. Director David H. Deming was granted 23,800 restricted stock units, vesting in one year.

Summary

• Director David H. Deming of Phio Pharmaceuticals Corp. was granted 23,800 shares underlying restricted stock units (RSUs).
• These restricted stock units will vest on the first annual anniversary of the grant date.
• The transaction occurred on February 5, 2026, with a reported price of $0 per share, indicating a grant.
• Following this transaction, Deming beneficially owns 37,800 shares, which includes these newly granted units and other previously held unvested restricted stock units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine, slightly positive event, indicating continued alignment of a director's interests with the company's long-term performance through equity compensation.

Positives

• The grant of restricted stock units to Director David H. Deming aligns his interests with long-term shareholder value.
• The vesting schedule encourages continued commitment and performance from a key director.

Risks

• The value of the granted restricted stock units is subject to the future performance of Phio Pharmaceuticals Corp.'s common stock.
• Unvested restricted stock units represent potential future dilution upon vesting, though this is a standard aspect of equity compensation.

Future Outlook

The filing indicates a future vesting event for the restricted stock units on the first annual anniversary of the grant date (February 5, 2027, assuming the grant date is February 5, 2026). This suggests a continued long-term incentive for the director.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through restricted stock units, is a common practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize key personnel, including directors, by aligning their financial interests with the company's long-term performance.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard practice in the biotech sector, comparable to compensation structures at companies like Moderna or BioNTech, which frequently use equity to incentivize leadership.
• A $0 transaction price for RSUs is typical, as these are grants rather than purchases, reflecting compensation for service rather than an investment at market price.

Related Party Transactions

• The grant of restricted stock units to a director constitutes a related-party transaction, which is a standard form of executive and director compensation.

Stakeholder Impact

• Shareholders: Potential minor future dilution upon vesting, but also increased alignment of the director's interests with shareholder value.
• Employees: No direct impact mentioned in this filing.

Next Steps

• The 23,800 restricted stock units will vest on the first annual anniversary of the grant date (February 5, 2027).

Key Dates

Recommendation

This Form 4 filing reports a standard equity compensation grant to a director and does not contain information that would fundamentally alter the investment thesis for Phio Pharmaceuticals Corp. It reinforces director alignment but provides no new operational or financial data to warrant a change in recommendation.

Keywords

Phio Pharmaceuticals, PHIO, Restricted Stock Units, RSU, Insider Transaction, Form 4, Equity Compensation, Director Grant